Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE: abemaciclib plus adjuvant endocrine therapy versus adjuvant endocrine therapy alone in high-risk HR-positive/HER2-negative early breast cancer
NL-OMON56125Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive disease-free survival. Started Dec 2017; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON56125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56125.